Building the Future of
Israeli Biotech


Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israeli-based biotech companies.

Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs. We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance. The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.


“We invest in Israeli and Israeli related biotechnology and pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential.”

Our key asset is a unique team of nearly 30 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.

We provide our portfolio companies with the necessary resources for long-term sustainable growth. We provide them with access to network, executive talent, strategic, operational, and business development resources.

This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.


Ayala Pharmaceuticals

A clinical-stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers.

Board Members: David Sidransky, MD, Robert Spiegel, MD, Murray Goldberg


Biond Biologics

A pre-clinical pharmaceutical company, Developing unique, creative and breakthrough immuno-therapies for oncology and autoimmune diseases.

Board Member: Yuval Cabilly, PhD


Gamida Cell

A clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases.

Cell therapy

Pharma Two B

A clinical-stage pharmaceutical company that is developing differentiated and value-added products, based on previously approved drugs, with a lead product candidate being investigated as treatment for early stage Parkinson’s disease.

Board Member: Jeff Kindler



A pre-clinical pharmaceutical company developing a breakthrough new immunomodulatory compound for autoimmune diseases.

Board Member: Yuval Cabilly, PhD



A pre-clinical biotech company developing  novel drug candidates targeting major splicing mutations in genetic diseases, focusing on splicing mutations in the CFTR gene for treatment of Cystic Fibrosis patients.

Board Members: Stanley Fiel, MD, Ido Zairi



Venture Advisors


CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) …

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

– Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ — SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including …

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares …


Israel Biotech Fund
Ruhrberg Science Center,
Bell Entrance, 4th Floor
3 Pekeris Street, Rabin Science Park
Rehovot 7670212, Israel

Parking (payable) available at the building.
Entrance from HaMada St.
Additional parking (payable via app) available at
a parking lot on Pekeris St. next to the building.


We would be happy to hear from you
and learn more about your company and
technology. Please feel free to contact us at
[email protected]